Allison Betof Warner

Academic History

Allison Betof Warner, MD, PhD, is a board-certified, fellowship-trained Medical Oncologist specializing in advanced melanoma treatment. She serves as the Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy, and co-Director of the Pigmented Lesion and Melanoma Program at Stanford Medicine, Stanford, CA. Dr Betof Warner has made significant contributions to the field as a pioneer in tumor infiltrating lymphocyte (TIL) therapy, leading the Melanoma Cutaneous Oncology Clinical Research Group, which focuses on tumor response to immunotherapy.

In addition to her clinical roles, Dr Betof Warner is an Assistant Professor in the Department of Medicine, Division of Medical Oncology. She is an active member of several professional organizations, including the American Association for Cancer Research, the American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer, where she serves on the Early Career Scientist Committee. She is also a member of the American College of Sports Medicine and the European Society for Medical Oncology.

Speaking on innovative approaches to melanoma treatment and cellular therapies

Dr Betof Warner has actively participated in multiple clinical trials, including the promising IMA203 trial, which explores genetic engineering of TILs and T-cell receptor therapies to enhance efficacy in treating refractory melanoma. Her ongoing research continues to advance treatment strategies for melanoma, particularly in the areas of central nervous system metastases and novel cellular therapies. Dr Betof Warner’s contributions to the field have been recognized by prestigious organizations, including the American Society of Clinical Oncology (ASCO), Melanoma Research Foundation, and National Institutes of Health (NIH).